The importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment.
Gary D. Novack, PhD
Advertisement
Articles by Gary D. Novack, PhD
Advertisement
Latest Updated Articles
- Novel therapies abound in pipeline
Published: July 1st 2017 | Updated: January 7th 2022
Advertisement
Advertisement